Mallinck­rodt con­sid­ers Chap­ter 11 as ‘ad­vanced dis­cus­sions’ con­tin­ue

Mallinck­rodt is con­sid­er­ing fil­ing for Chap­ter 11 bank­rupt­cy for the sec­ond time in three years as it again de­lays mak­ing a pay­ment re­quired as part of its $1.7 bil­lion opi­oid set­tle­ment.

The Irish drug­mak­er said Tues­day in an SEC fil­ing that it is in the mid­dle of “ad­vanced dis­cus­sions” about the pos­si­bil­i­ty of a re­struc­tur­ing sup­port agree­ment.

The com­pa­ny pushed back mak­ing a $200 mil­lion pay­ment re­quired as part of the opi­oid set­tle­ment for the sec­ond time. It was orig­i­nal­ly due June 16; that due date was moved to Aug. 15 and is now Aug 22. It has al­so missed in­ter­est pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER